ANTELLIQ acquired by MERCK & CO.

The global life sciences leader has finalized the acquisition of 100% of the share capital of the target from a prominent European private equity firm. This strategic transaction represents a definitive move to incorporate advanced digital capabilities into the group’s specialized animal health division, targeting the high-growth segment of animal intelligence and monitoring. The strategic rationale for the move centers on the acquirer's objective to provide integrated, data-driven health management solutions that complement its existing portfolio of vaccines and medicines. By incorporating this technical specialist, the organization reinforces its ability to offer comprehensive traceability and real-time health insights for livestock and companion animals. The partnership is designed to leverage the acquirer’s global reach and research infrastructure to accelerate the development of next-generation monitoring technologies. This integration facilitates the creation of a premier digital platform in the animal health market, providing the strategic depth required to address the rising demand for food security and enhanced pet longevity.

In the past, the company had already been the subject of several LBOs, notably led by Bc Partners in 2013 and Psp Investments in 2016. These multiple LBO cycles illustrate the strong appeal for this type of asset.